Exploring Imaging Biomarkers in the Diagnosis of Alzheimer’s Disease across the Age Span
Tammie Benzinger, MD, PhD, discusses the use of imaging biomarkers in the diagnosis of Alzheimer’s disease across the age span, with discussion on how these imaging biomarkers differ in early-onset compared with late-onset Alzheimer’s disease. She discusses the imaging biomarker results in the patient case study, as well as highlighting some of the system constraints involved in imaging in Alzheimer’s disease. Philip Scheltens then discusses the MRI results in the patient case study, alongside additional assessments including genetic screening, PET imaging, and CSF biomarkers.
Key Learning Objectives for Biogen’s AAT-AD/PD 2020 Symposium:
- Understand the importance of an early diagnosis of Alzheimer’s disease
- Assess the current healthcare system readiness for a paradigm shift to early diagnosis
- Gain insights on how cognitive assessment tools and imaging biomarkers can be used to distinguish between different subtypes of Alzheimer’s disease
- Increase understanding of the differences between the pathology of familial or sporadic early-onset and late-onset Alzheimer’s disease
Disclosure: All panelists received honoraria from Biogen for participation in this symposium.
Disclaimer: All of the information discussed today is for informational purposes only; does not constitute medical advice; and is not intended to be a substitute for independent professional medical judgment, advice, diagnosis, or treatment.